Reversal of excessive effect of regular anticoagulation: Low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation

V. Pengo, A. Banzato, E. Garelli, A. Zasso, A. Biasiolo

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

To determine the best way to reverse the excessive effect of regular anticoagulation in patients with INR > 5 and no bleeding complications, 23 patients with INR > 5 were randomly subdivided into two groups: group A (n = 12) discontinued warfarin for one day and group B (n = 11) received 2 mg of vitamin K1 orally in addition to the usual warfarin dose. INR was determined after 24 h (day 1), after which both groups continued with their usual dose of warfarin. After 48 h (day 2), warfarin dosage was changed according to the INR value. On day 9, INR values were determined again. Five out of twelve patients in group A had INR values > 5 on day 1. One patient in group A had an INR value <5 both on days 1 and 2. All eleven patients in group B had INR values <5 on day 1, and all but one on day 2. On day 9, INR values were acceptable (INR 2.0-4.5) in ten group A patients and eight group B patients. These findings suggest that a low oral dose of vitamin K1 is a convenient treatment for excessive anticoagulation in patients with no bleeding complications.

Original languageEnglish
Pages (from-to)739-741
Number of pages3
JournalBlood Coagulation and Fibrinolysis
Volume4
Issue number5
Publication statusPublished - 1993

Fingerprint

Vitamin K 1
International Normalized Ratio
Warfarin
Hemorrhage

Keywords

  • oral anticoagulants
  • vitamin K International Normalized Ratio (INR)

ASJC Scopus subject areas

  • Hematology

Cite this

Reversal of excessive effect of regular anticoagulation : Low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. / Pengo, V.; Banzato, A.; Garelli, E.; Zasso, A.; Biasiolo, A.

In: Blood Coagulation and Fibrinolysis, Vol. 4, No. 5, 1993, p. 739-741.

Research output: Contribution to journalArticle

@article{8ecd7c5926af45aab8fe78d38529b59e,
title = "Reversal of excessive effect of regular anticoagulation: Low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation",
abstract = "To determine the best way to reverse the excessive effect of regular anticoagulation in patients with INR > 5 and no bleeding complications, 23 patients with INR > 5 were randomly subdivided into two groups: group A (n = 12) discontinued warfarin for one day and group B (n = 11) received 2 mg of vitamin K1 orally in addition to the usual warfarin dose. INR was determined after 24 h (day 1), after which both groups continued with their usual dose of warfarin. After 48 h (day 2), warfarin dosage was changed according to the INR value. On day 9, INR values were determined again. Five out of twelve patients in group A had INR values > 5 on day 1. One patient in group A had an INR value <5 both on days 1 and 2. All eleven patients in group B had INR values <5 on day 1, and all but one on day 2. On day 9, INR values were acceptable (INR 2.0-4.5) in ten group A patients and eight group B patients. These findings suggest that a low oral dose of vitamin K1 is a convenient treatment for excessive anticoagulation in patients with no bleeding complications.",
keywords = "oral anticoagulants, vitamin K International Normalized Ratio (INR)",
author = "V. Pengo and A. Banzato and E. Garelli and A. Zasso and A. Biasiolo",
year = "1993",
language = "English",
volume = "4",
pages = "739--741",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Reversal of excessive effect of regular anticoagulation

T2 - Low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation

AU - Pengo, V.

AU - Banzato, A.

AU - Garelli, E.

AU - Zasso, A.

AU - Biasiolo, A.

PY - 1993

Y1 - 1993

N2 - To determine the best way to reverse the excessive effect of regular anticoagulation in patients with INR > 5 and no bleeding complications, 23 patients with INR > 5 were randomly subdivided into two groups: group A (n = 12) discontinued warfarin for one day and group B (n = 11) received 2 mg of vitamin K1 orally in addition to the usual warfarin dose. INR was determined after 24 h (day 1), after which both groups continued with their usual dose of warfarin. After 48 h (day 2), warfarin dosage was changed according to the INR value. On day 9, INR values were determined again. Five out of twelve patients in group A had INR values > 5 on day 1. One patient in group A had an INR value <5 both on days 1 and 2. All eleven patients in group B had INR values <5 on day 1, and all but one on day 2. On day 9, INR values were acceptable (INR 2.0-4.5) in ten group A patients and eight group B patients. These findings suggest that a low oral dose of vitamin K1 is a convenient treatment for excessive anticoagulation in patients with no bleeding complications.

AB - To determine the best way to reverse the excessive effect of regular anticoagulation in patients with INR > 5 and no bleeding complications, 23 patients with INR > 5 were randomly subdivided into two groups: group A (n = 12) discontinued warfarin for one day and group B (n = 11) received 2 mg of vitamin K1 orally in addition to the usual warfarin dose. INR was determined after 24 h (day 1), after which both groups continued with their usual dose of warfarin. After 48 h (day 2), warfarin dosage was changed according to the INR value. On day 9, INR values were determined again. Five out of twelve patients in group A had INR values > 5 on day 1. One patient in group A had an INR value <5 both on days 1 and 2. All eleven patients in group B had INR values <5 on day 1, and all but one on day 2. On day 9, INR values were acceptable (INR 2.0-4.5) in ten group A patients and eight group B patients. These findings suggest that a low oral dose of vitamin K1 is a convenient treatment for excessive anticoagulation in patients with no bleeding complications.

KW - oral anticoagulants

KW - vitamin K International Normalized Ratio (INR)

UR - http://www.scopus.com/inward/record.url?scp=0027520669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027520669&partnerID=8YFLogxK

M3 - Article

C2 - 8292723

AN - SCOPUS:0027520669

VL - 4

SP - 739

EP - 741

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 5

ER -